Early abciximab administration before transfer for primary percutaneous coronary interventions for ST-elevation myocardial infarction reduces 1-year mortality in patients with high-risk profile. Results from EUROTRANSFER Registry
- 31 October 2009
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 158 (4) , 569-575
- https://doi.org/10.1016/j.ahj.2009.08.008
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- European registry on patients with ST-elevation myocardial infarction transferred for mechanical reperfusion with a special focus on early administration of abciximab—EUROTRANSFER RegistryAmerican Heart Journal, 2008
- Management of acute myocardial infarction in patients presenting with persistent ST-segment elevationEuropean Heart Journal, 2008
- Facilitated PCI in Patients with ST-Elevation Myocardial InfarctionNew England Journal of Medicine, 2008
- 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial InfarctionCirculation, 2008
- Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-upEuropean Heart Journal, 2007
- Beneficial effects of abciximab in patients with primary percutaneous intervention for acute ST segment elevation myocardial infarction in clinical practiceHeart, 2006
- Abciximab as Adjunctive Therapy to Reperfusion in Acute ST-Segment Elevation Myocardial InfarctionJAMA, 2005
- A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarctionJournal of the American College of Cardiology, 2003
- Comparison of Angioplasty with Stenting, with or without Abciximab, in Acute Myocardial InfarctionNew England Journal of Medicine, 2002
- TIMI Risk Score for ST-Elevation Myocardial Infarction: A Convenient, Bedside, Clinical Score for Risk Assessment at PresentationCirculation, 2000